A randomized, double blind, placebo-controlled, multicen

Project: Research project

Project Details

Description

A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
StatusFinished
Effective start/end date2/28/132/25/18

Funding

  • BAYER HEALTHCARE PHARMACEUTICALS

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.